Inflammation icon large

At Blueberry Therapeutics, drug discovery always starts with a thorough appreciation of patients’ needs. We then seek out innovative new approaches to develop medicines that meet these needs.

Blueberry is developing a range of therapies aimed at treating inflammatory diseases. Inflammation is a normal physiological response to a range of harmful stimuli such as irritation, tissue damage or infection and is characterised by redness, swelling and discomfort (pain or itch). Inflammation is part of the body’s innate immune response and usually clears up. However, in some circumstances the inflammatory response  does not resolve resulting in chronic inflammation that is the underlying root cause of a number of diseases. We are developing new therapies to such disorders using potent peptide aptamers targeted to key mechanisms in inflammation.

Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) is a group of serious disorders in which the intestines become inflamed and is one of the most prevalent gastrointestinal diseases in the United States. Patients with IBD suffer from a range of uncomfortable and debilitating symptoms including diarrhoea and abdominal pain. IBD can also lead to potentially life-threatening complications such as perforation (rupture) of the bowl and patients with IBD may have an increased likelihood of developing bowel cancer. Blueberry is tackling the huge unmet medical need in the treatment of IBD by targeting key inflammatory mechanisms in IBD using peptide-apatmers delivered with state-of-the-art nanopolymer drug delivery systems.

Atopic Dermatitis

Atopic dermatitis (AD) is a chronic, relapsing inflammatory disease of the skin  affecting up to 20% of children and 3% of adults and is increasingly common in industrialised countries. Current therapies for the treatment of AD have significant side effects that limit their use. Blueberry is developing new safer medicines that will address  three of the four key mechanisms of AD: inflammation, itch and bacterial colonisation.


Acne is a very common skin complaint that affects over 90% of individuals during their lifetime. Symptoms range from mild, only a few spots, to severe cases with many deep, inflamed and infected spots that may result in permanent scarring. Blueberry is developing new treatments for all forms of acne which tackle both inflammation and infection associated with the disorder.

Example of Eczema

Example of Dermatitis

Example of Acne

Example of severe acne

Drugs in our pipeline
Patents and exclusives licences
Billion dollars in commercial potential